Abstract:BACKGROUND:It is widely accepted that inflammatory cytokine, interleukin 6 (IL-6), was not only elevated in cancer but also important in carcinogenesis. But how did IL-6 be produced in tumor microenvironment remains to be addressed.METHODS:Both bioinformatics tools and quantitative real time polymerase chain reaction (RT-PCR) were used to examine the expression of IL-6 in cancer cells. To map super-enhancers of IL-6, sgRNAs were constructed. Stable knockout cells were established and subsequently used for cell proliferation and colony formation assay. The correlation between mapped super-enhancers and IL-6 expression was studied by ATAC-seq analysis.RESULTS:The expression of IL-6 was high in multiple cancers, including pancreatic cancer (PAAD). The elevated expression of IL-6 in PAAD was further confirmed by transcriptional data and in a panel of pancreatic cancer cell lines (one immortal HPDE6-C7 cell line and four PDAC cell lines: BxPC-3, PANC-1, AsPC-1 and CFPAC-1). When treated with JQ-1 and I-BET-762, two inhibitors of super-enhancers, the expression of IL-6 in multiple cancer cells including CFPAC-1, HeLa and SUM-159 cells was significantly reduced. By analyzing the H3K27Ac profiling, BRD4 binding, Med1 binding and DNA conservation in CFPAC-1, HeLa and SUM-159 cells, we identified a potential super-enhancer (IL6-SE) that might be important for IL-6 expression in cancer. The super-enhancer (IL6-SE) can be further divided into two elements (IL6-SEa and IL6-SEb). Genetic deletion of IL6-SEa in cancer cells greatly reduces the expression of IL-6. IL6-SEa deficient cells also showed low proliferation and colony formation ability. In patients, the epigenetic activation (ATAC signal) of IL6-SEa is correlated with the expression of IL-6.CONCLUSIONS:In summary, we not only provide convincing experimental evidence to demonstrate that IL-6 expression in cancer is dependent on super-enhancers but also identified IL6-SEa as a critical DNA regulatory element. Our findings provide new insights to understand the epigenetic regulation of IL-6 expression in cancers.

Super-Enhancer Induced IL-20RA Promotes Proliferation/Metastasis and Immune Evasion in Colorectal Cancer

Aberrantly Expressed Fra-1 by Il-6/Stat3 Transactivation Promotes Colorectal Cancer Aggressiveness Through Epithelial-Mesenchymal Transition

IL-13/STAT6 Signaling Plays a Critical Role in the Epithelial-Mesenchymal Transition of Colorectal Cancer Cells.

Genome-wide Profiling in Colorectal Cancer Identifies PHF19 and TBC1D16 As Oncogenic Super Enhancers

Interleukin 20 Receptor A Expression in Colorectal Cancer and Its Clinical Significance

Genome-wide profiling of active enhancers in colorectal cancer

LINC00460/miR-186-3p/MYC feedback loop facilitates colorectal cancer immune escape by enhancing CD47 and PD-L1 expressions

The Role of Interleukin-17A in Colorectal Tumorigenesis

Recurrent Superenhancer of the Oncogene POU5F1B in Colorectal Cancers

Super-enhancers Modulate Interleukin-6 Expression and Function in Cancers.

IGF1-mediated HOXA13 Overexpression Promotes Colorectal Cancer Metastasis Through Upregulating ACLY and IGF1R

A20 Promotes Colorectal Cancer Immune Evasion by Upregulating STC1 Expression to Block “Eat-Me” Signal

Abstract 1688: Nuclear receptor coactivator SRC-1 promotes colorectal cancer immune escape by enhancing PD-L1 transcription and protein stability

Targeting super-enhancer activity for colorectal cancer therapy

IL-22(+)CD4(+) T Cells Promote Colorectal Cancer Stemness Via STAT3 Transcription Factor Activation and Induction of the Methyltransferase DOT1L.

IL-22+CD4+ T Cells Promote Colorectal Cancer Stemness Via STAT3 Transcription Factor Activation and Induction of the Methyltransferase DOT1L (TUM10P.1022)

LINC00543 promotes colorectal cancer metastasis by driving EMT and inducing the M2 polarization of tumor associated macrophages

CASC21, a FOXP1 Induced Long Non-Coding RNA, Promotes Colorectal Cancer Growth by Regulating CDK6.

Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression

IL25 Enhanced Colitis-Associated Tumorigenesis in Mice by Upregulating Transcription Factor GLI1.

KIF20A Promotes CRC Progression and the Warburg Effect through the C-Myc/HIF-1α Axis